An important limitation of imatinib, the first-line treatment for the vast majority of worldwide CML patients, is that survival of CML-LSCs is not dependent from BCR-ABL activity. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.